Interpace Biosciences: Up on increased Medicare coverage for thyroid cancer test

Interpace Biosciences

17/12/2019 15:08

** Diagnostics company's  IDXG.O  shares rise 8.27% to 50
cents
    ** IDXG's thyroid cancer diagnosis test ThyGeNEXT is in the
process of receiving an additional $2,400 in reimbursement under
Medicare  urn:newsml:reuters.com:*:nGNX8sx0q5
    ** Company expects final approval in Q1 of 2020
    ** Increased reimbursement rate reflects ThyGeNEXT's
expansion from identifying thyroid cancer in patients to
determining whether patients need surgery
    ** IDXG, formerly Interpace Diagnostics, had launched
ThyGeNEXT in May 2018 and processed ~12,500 ThyGeNEXT tests by
end 2018
    ** Up to Monday's close, stock had fallen 42.3%

 (Reporting by Ruhi Soni in Bengaluru)
 ((Ruhi.Soni@thomsonreuters.com;))